Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevnar 13 in severe chronic kidney disease
NCT02370069Phase 4Completed
- Sponsor
- Lakehead University
- Start
- Jun 2015
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 13 in pneumococcal infection (2 arms), sponsored by Lakehead University. Primary endpoints: Fold increase in serotype-specific antibody levels at 28 days and Increase in opsonophagocytic activity titres at 28 days. Started Jun 2015; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02370069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370069.